DLBCL
MCID: DFF005
MIFTS: 59

Diffuse Large B-Cell Lymphoma (DLBCL) malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

Aliases & Descriptions for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma 38 12 50 14 69
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified 69
Dlbcl 50

Classifications:



External Ids:

Disease Ontology 12 DOID:0050745
ICD10 33 C83.3

Summaries for Diffuse Large B-Cell Lymphoma

NIH Rare Diseases : 50 diffuse large b-cell lymphoma (dlbcl), a form of non-hodgkin lymphoma, is the most common blood cancer. lymphomas occur when cells of the immune system, known as b lymphocytes, grow and multiply uncontrollably. dlbcl occurs mostly in adults and is an aggressive (fast-growing) lymphoma. it can arise in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. often, the first sign of dlbcl is a painless rapid swelling in the neck, armpit, abdomen, or groin which is caused by enlarged lymph nodes. for some patients, the swelling may be painful. other symptoms include night sweats, unexplained fevers, and weight loss. the prognosis and treatment may differ depending on the location of the tumor and the subtype of lymphoma. however, a combination of chemotherapy and the monoclonal antibody rituximab (rituxan) (r-chop) is a widely used treatment for patients with advanced dlbcl.. a stem cell transplant may be indicated for dlbcl patients whose cancer has returned or relapsed. last updated: 6/28/2016

MalaCards based summary : Diffuse Large B-Cell Lymphoma, also known as diffuse large b-cell lymphoma, not otherwise specified, is related to primary cutaneous diffuse large b-cell lymphoma, leg type and epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly. An important gene associated with Diffuse Large B-Cell Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Innate Immune System and Apoptosis Modulation and Signaling. The drugs rituximab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and t cells, and related phenotypes are immune system and hematopoietic system

Disease Ontology : 12 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
id Related Disease Score Top Affiliating Genes
1 primary cutaneous diffuse large b-cell lymphoma, leg type 12.5
2 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 12.5
3 diffuse large b-cell lymphoma of the central nervous system 12.5
4 diffuse large b-cell lymphoma with chronic inflammation 12.4
5 gray zone lymphoma 11.6
6 lymphoma 11.4
7 b-cell lymphomas 11.4
8 reticulosarcoma 11.2
9 mediastinal gray zone lymphoma 11.2
10 plasmablastic lymphoma 10.9
11 primary mediastinal large b-cell lymphoma 10.9
12 intravascular large b-cell lymphoma 10.9
13 primary central nervous system lymphoma 10.8
14 t-cell/histiocyte rich large b cell lymphoma 10.8
15 follicular lymphoma 10.5
16 hodgkin lymphoma 10.5
17 burkitt lymphoma 10.4
18 alk-positive large b-cell lymphoma 10.4
19 leukemia 10.4
20 peripheral t-cell lymphoma 10.4
21 hepatitis 10.3
22 prinzmetal's variant angina 10.3 BCL6 IRF4 MYC
23 symptomatic form of hemophilia a in female carriers 10.3 IRF4 MYD88
24 mediastinitis 10.3
25 rubella panencephalitis 10.3 BCL6 MALT1
26 tongue squamous cell carcinoma 10.3 FOXP1 MME MYD88
27 rommen mueller sybert syndrome 10.3 CDK4 MDM2 TP53
28 angioimmunoblastic t-cell lymphoma 10.3
29 mantle cell lymphoma 10.3
30 extraosseous osteosarcoma 10.3 CDK4 MDM2 MYC
31 trigeminal nerve neoplasm 10.3 CD5 MME
32 ethmoid sinus inverted papilloma 10.3 BCL6 MME
33 barnicoat baraitser syndrome 10.3 CD5 MYC TP53
34 tall cell variant papillary carcinoma 10.3 BCL6 MME MYC
35 brain stem angioblastoma 10.3 CDK4 MDM2 TP53
36 coloboma of eyelid 10.3 BCL6 CD5 MME
37 house allergic alveolitis 10.3 CDK4 MDM2 TP53
38 gingival recession 10.3 BCL6 IRF4 MME MYC
39 anterior foramen magnum meningioma 10.3 BCL6 MYC TP53
40 enchondromatosis dwarfism deafness 10.3 CDK4 MDM2 TP53
41 childhood brain stem glioma 10.3 CD5 MME TP53
42 multifocal osteogenic sarcoma 10.3 CDK4 MDM2 MYC
43 endotheliitis 10.3
44 chronic lymphocytic leukemia 10.3
45 hyperphosphatasia with mental retardation syndrome 2 10.2 FOXP1 MME MYC TP53
46 extraocular retinoblastoma 10.2 CDK4 MDM2 MYC TP53
47 interstitial lung disease 10.2 CDK4 MDM2 TP53
48 integumentary system benign neoplasm 10.2 CDK4 MDM2 MYC TP53
49 post-surgical hypoinsulinemia 10.2 CDK4 MDM2 MYC TP53
50 duodenal ulcer 10.2 CD5 IRF4 MYC TP53

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:



Diseases related to Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

MGI Mouse Phenotypes related to Diffuse Large B-Cell Lymphoma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.32 IRF4 LMO2 MALT1 MDM2 MME MYC
2 hematopoietic system MP:0005397 10.31 BCL10 BCL6 CARD11 CD5 CDK4 EZH2
3 cellular MP:0005384 10.22 BCL10 BCL6 CDK4 EZH2 LMO2 MDM2
4 cardiovascular system MP:0005385 10.19 BCL6 CDK4 EZH2 LMO2 MDM2 MYC
5 endocrine/exocrine gland MP:0005379 10.13 BCL10 BCL6 CDK4 EZH2 MDM2 MYC
6 embryo MP:0005380 10.11 BCL10 CDK4 EZH2 LMO2 MDM2 MYC
7 integument MP:0010771 10.02 LMO2 MDM2 MME MYC REL TP53
8 liver/biliary system MP:0005370 9.91 BCL6 CDK4 LMO2 MDM2 MME MYC
9 neoplasm MP:0002006 9.81 EZH2 IRF4 LMO2 MDM2 MYC MYD88
10 no phenotypic analysis MP:0003012 9.56 MDM2 MYC MYD88 PRDM1 TP53 BCL6
11 normal MP:0002873 9.28 BCL6 CD5 CDK4 EZH2 MDM2 MYC

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 527)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
6
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
7
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
8
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
12
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
15
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
17
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
20
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
21 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
24 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
28 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
33 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
39 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1
41 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
42 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
45 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1281)
id Name Status NCT ID Phase
1 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4
2 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
4 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
5 Treatment of Diffuse Large B Cell Lymphoma Recruiting NCT01949818 Phase 4
6 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4
7 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4
8 Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Unknown status NCT00846157 Phase 3
9 Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Unknown status NCT00499018 Phase 3
10 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
11 Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R Unknown status NCT00322218 Phase 3
12 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
13 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3
14 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
15 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
16 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
17 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
18 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
19 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
20 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
21 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3
22 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00003815 Phase 3
23 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3
24 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3
25 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
26 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3
27 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3
28 ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 Completed NCT00140595 Phase 3
29 R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma Completed NCT00144755 Phase 3
30 Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV Completed NCT00286832 Phase 3
31 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3
32 ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3
33 R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma Completed NCT00137995 Phase 3
34 A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma Completed NCT01649856 Phase 3
35 R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL Completed NCT01148446 Phase 3
36 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Completed NCT01014208 Phase 3
37 Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma Completed NCT00052923 Phase 3
38 Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma Completed NCT01459887 Phase 3
39 Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. Completed NCT00355199 Phase 3
40 Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma Completed NCT00566228 Phase 3
41 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed NCT00719472 Phase 3
42 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3
43 Zevalin-beam for Aggressive Lymphoma Completed NCT00491491 Phase 3
44 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed NCT00332202 Phase 3
45 Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00064116 Phase 3
46 Rituxan vs Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (BMT CTN 0401) Completed NCT00329030 Phase 3
47 Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00012051 Phase 3
48 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
49 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3
50 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Diffuse Large B-Cell Lymphoma

Anatomical Context for Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Diffuse Large B-Cell Lymphoma:

39
B Cells, Bone, T Cells, Breast, Skin, Thyroid, Lymph Node

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 1742)
id Title Authors Year
1
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. ( 28403071 )
2017
2
TET2 mutation in diffuse large B-cell lymphoma. ( 28331128 )
2017
3
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. ( 28041583 )
2017
4
Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. ( 28103885 )
2017
5
Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma. ( 28057019 )
2017
6
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ( 28060891 )
2017
7
3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro. ( 28054086 )
2017
8
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
9
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. ( 28507339 )
2017
10
Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. ( 28058506 )
2017
11
Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma. ( 28059091 )
2017
12
Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation. ( 28069035 )
2017
13
Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for the treatment of diffuse large B-cell lymphoma and Burkitt lymphoma. ( 28385782 )
2017
14
Inflammatory Biomarkers in Diffuse Large B-Cell Lymphoma: Time for Extending the Established Prognosis Scores? ( 28076864 )
2017
15
Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). ( 28076329 )
2017
16
A Case of Therapy-Related Acute Leukemia With Mixed Phenotype With BCR-ABL1 After Treatment of Diffuse Large B-Cell Lymphoma. ( 28029006 )
2017
17
Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. ( 28076862 )
2017
18
Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma. ( 28039708 )
2016
19
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. ( 26585955 )
2016
20
Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma. ( 27077767 )
2016
21
Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. ( 27460179 )
2016
22
Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas. ( 27391453 )
2016
23
Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas. ( 27356265 )
2016
24
Coexistent adrenal diffuse large B cell lymphoma in a patient with WaldenstrAPm's macrogloblinemia/lymphoplasmacytic lymphoma. ( 27365139 )
2016
25
Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma. ( 27187305 )
2016
26
Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. ( 26752547 )
2016
27
Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. ( 28035434 )
2016
28
CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. ( 26414904 )
2016
29
Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas. ( 27863378 )
2016
30
Immunoproliferative Small Intestinal Disease Associated with Overwhelming Polymicrobial Gastrointestinal Infection with Transformation to Diffuse Large B-cell Lymphoma. ( 26903604 )
2016
31
Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B-cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. ( 28032914 )
2016
32
EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features. ( 26780579 )
2016
33
Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP. ( 27196819 )
2016
34
Expression of the activation markers Blimp1, Foxp1 and pStat3 in extranodal diffuse large B-cell lymphomas. ( 27924626 )
2016
35
Different predictive values of interim (18)F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma. ( 27627889 )
2016
36
High prevalence of diffuse large B-cell lymphoma in occult hepatitis B virus-infected patients in the Tohoku district in Eastern Japan. ( 27219865 )
2016
37
Extra-nodal Diffuse Large B-cell Lymphoma (Germinal Center Type) Manifesting as Non-healing Extraction Socket. ( 27656575 )
2016
38
A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. ( 27708232 )
2016
39
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. ( 27643872 )
2016
40
FcI^RIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk. ( 28039707 )
2016
41
The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. ( 27324387 )
2016
42
Diffuse large B-cell lymphoma and polycythemia vera discovered at the onset - a rare association and its possible importance in lymphoma prognosis. ( 27151728 )
2016
43
Biological correlation between glucose transporters, Ki-67 and 2-deoxy-2-[18F]-fluoro-D-glucose uptake in diffuse large B-cell lymphoma and natural killer/T-cell lymphoma. ( 27173341 )
2016
44
Diffuse large B-cell lymphoma occurring in an ovarian cystic teratoma: expanding the spectrum of large B-cell lymphoma associated with chronic inflammation. ( 26980033 )
2016
45
Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy. ( 26077666 )
2016
46
Ascites as the initial characteristic manifestation in a patient with primary gastric CD8-positive diffuse large B-cell lymphoma. ( 27212160 )
2016
47
Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma. ( 27172795 )
2016
48
Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP. ( 27661033 )
2016
49
Discordant lymphoma of duodenal EBV-positive peripheral T-cell lymphoma not otherwise specified and ileal diffuse large B-cell lymphoma. ( 27169448 )
2016
50
CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. ( 26340843 )
2016

Variations for Diffuse Large B-Cell Lymphoma

Cosmic variations for Diffuse Large B-Cell Lymphoma:

9 (show top 50) (show all 126)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11059 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.713G>A p.C238Y 6
2 COSM45035 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.761T>G p.I254S 6
3 COSM43967 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.751A>T p.I251F 6
4 COSM43942 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.425C>A p.P142H 6
5 COSM44327 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.518T>C p.V173A 6
6 COSM45416 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.524G>C p.R175P 6
7 COSM43963 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.396G>C p.K132N 6
8 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.817C>T p.R273C 6
9 COSM10690 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.473G>A p.R158H 6
10 COSM10834 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.711G>A p.M237I 6
11 COSM44171 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.840A>T p.R280S 6
12 COSM43936 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.857A>T p.E286V 6
13 COSM10654 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.637C>T p.R213* 6
14 COSM44345 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.915G>T p.K305N 6
15 COSM10742 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.578A>G p.H193R 6
16 COSM44821 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.412G>A p.A138T 6
17 COSM43842 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.770T>C p.L257P 6
18 COSM44463 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.848G>T p.R283L 6
19 COSM10704 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.844C>T p.R282W 6
20 COSM43970 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.380C>A p.S127Y 6
21 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.524G>A p.R175H 6
22 COSM43935 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.577C>A p.H193N 6
23 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.743G>A p.R248Q 6
24 COSM43606 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.734G>A p.G245D 6
25 COSM10705 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.586C>T p.R196* 6
26 COSM44338 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.845G>A p.R282Q 6
27 COSM44948 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.526T>C p.C176R 6
28 COSM44030 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.760A>G p.I254V 6
29 COSM43848 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.472C>T p.R158C 6
30 COSM10647 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.404G>T p.C135F 6
31 COSM43559 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.517G>T p.V173L 6
32 COSM43903 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.470T>G p.V157G 6
33 COSM6932 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.733G>A p.G245S 6
34 COSM10667 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.646G>A p.V216M 6
35 COSM10777 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.715A>G p.N239D 6
36 COSM43850 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.659A>C p.Y220S 6
37 COSM43947 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.614A>G p.Y205C 6
38 COSM44249 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.623A>T p.D208V 6
39 COSM43833 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.578A>C p.H193P 6
40 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.742C>T p.R248W 6
41 COSM11564 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.742C>G p.R248G 6
42 COSM43555 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.736A>G p.M246V 6
43 COSM43899 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.434T>C p.L145P 6
44 COSM44692 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.526T>G p.C176G 6
45 COSM43901 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.421T>C p.C141R 6
46 COSM10996 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.511G>T p.E171* 6
47 COSM43684 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.720T>G p.S240R 6
48 COSM10991 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.396G>T p.K132N 6
49 COSM11287 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.839G>T p.R280I 6
50 COSM44002 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.577C>G p.H193D 6

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

7 (show top 50) (show all 118)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13828 1 1 84900000 Loss Diffuse large b-cell lymphoma
2 17406 1 142600000 249250621 Gain Diffuse large b-cell lymphoma
3 20082 1 15300000 163800000 Gain Diffuse large b-cell lymphoma
4 38345 10 101900000 103000000 Gain Diffuse large b-cell lymphoma
5 38773 10 104900000 105800000 Gain Diffuse large b-cell lymphoma
6 38901 10 105800000 121700000 Loss Diffuse large b-cell lymphoma
7 40597 10 130600000 135534747 Loss Diffuse large b-cell lymphoma
8 43294 10 46100000 64500000 Loss Diffuse large b-cell lymphoma
9 48479 11 1 43500000 Gain Diffuse large b-cell lymphoma
10 51204 11 123900000 135006516 Loss Diffuse large b-cell lymphoma
11 53206 11 26100000 36400000 Loss Diffuse large b-cell lymphoma
12 55792 11 55700000 135006516 Gain Diffuse large b-cell lymphoma
13 64291 12 12600000 14800000 Gain CDKN1B Diffuse large b-cell lymphoma
14 70914 12 66000000 69800000 Gain MDM2 Diffuse large b-cell lymphoma
15 74343 13 104800000 110300000 Loss Diffuse large b-cell lymphoma
16 74383 13 105800000 109100000 Loss Diffuse large b-cell lymphoma
17 75387 13 19500000 55300000 Gain Diffuse large b-cell lymphoma
18 76712 13 35500000 75400000 Loss Diffuse large b-cell lymphoma
19 79280 13 68600000 115169878 Gain Diffuse large b-cell lymphoma
20 86223 14 55800000 61200000 Loss Diffuse large b-cell lymphoma
21 88116 14 84900000 107349540 Loss Diffuse large b-cell lymphoma
22 90236 15 20700000 102531392 Loss Diffuse large b-cell lymphoma
23 97251 16 1 34600000 Gain Diffuse large b-cell lymphoma
24 97373 16 1 7900000 Gain ABCA3 Diffuse large b-cell lymphoma
25 97375 16 1 7900000 Gain DCI Diffuse large b-cell lymphoma
26 97377 16 1 7900000 Gain E4F1 Diffuse large b-cell lymphoma
27 97379 16 1 7900000 Gain HAGH Diffuse large b-cell lymphoma
28 97381 16 1 7900000 Gain IGFALS Diffuse large b-cell lymphoma
29 97383 16 1 7900000 Gain MRPS34 Diffuse large b-cell lymphoma
30 97385 16 1 7900000 Gain NME3 Diffuse large b-cell lymphoma
31 97387 16 1 7900000 Gain NUBP2 Diffuse large b-cell lymphoma
32 97391 16 1 7900000 Gain RNPS1 Diffuse large b-cell lymphoma
33 99692 16 28100000 36600000 Loss Diffuse large b-cell lymphoma
34 102840 16 57400000 90354753 Gain Diffuse large b-cell lymphoma
35 102843 16 57400000 90354753 Loss Diffuse large b-cell lymphoma
36 104071 16 66700000 70800000 Gain DDX19 Diffuse large b-cell lymphoma
37 104073 16 66700000 70800000 Gain FUK Diffuse large b-cell lymphoma
38 104075 16 66700000 70800000 Gain SIAT4B Diffuse large b-cell lymphoma
39 106530 16 88700000 90354753 Gain Diffuse large b-cell lymphoma
40 106806 17 1 22200000 Loss Diffuse large b-cell lymphoma
41 111431 17 3600000 6800000 Loss TP53 Diffuse large b-cell lymphoma
42 120634 18 2900000 78077248 Gain Diffuse large b-cell lymphoma
43 121454 18 43500000 48200000 Gain Diffuse large b-cell lymphoma
44 121719 18 46400000 52000000 Gain BCL2 Diffuse large b-cell lymphoma
45 122173 18 53800000 56200000 Gain MALT1 Diffuse large b-cell lymphoma
46 123098 18 66800000 68700000 Loss Diffuse large b-cell lymphoma
47 123108 18 66900000 71300000 Gain Diffuse large b-cell lymphoma
48 127687 19 35500000 38300000 Gain KIRREL2 Diffuse large b-cell lymphoma
49 127689 19 35500000 38300000 Gain MLL4 Diffuse large b-cell lymphoma
50 127691 19 35500000 38300000 Gain NPHS1 Diffuse large b-cell lymphoma

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 35)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 BCL10 BCL6 CARD11 IRF4 MALT1 MDM2
2
Show member pathways
12.77 IRF4 MDM2 MYC MYD88 TP53
3
Show member pathways
12.64 BCL10 CARD11 MALT1 MYD88 REL
4
Show member pathways
12.64 BCL10 CARD11 MALT1 MDM2 REL TP53
5 12.45 EZH2 FOXP1 MDM2 MYC TP53
6
Show member pathways
12.34 MDM2 MYC REL TP53
7
Show member pathways
12.31 CDK4 MDM2 MYC TP53
8 12.3 CDK4 MDM2 MYC TP53
9
Show member pathways
12.26 BCL10 CARD11 CDK4 IRF4 MALT1 REL
11 12.23 CDK4 MDM2 REL TP53
12
Show member pathways
12.12 CDK4 MDM2 MYC TP53
13 12.09 CDK4 MDM2 MYC TP53
14
Show member pathways
12.07 BCL10 BCL6 CARD11 IRF4 MALT1 MYC
15 12.05 BCL6 LMO2 MDM2 MYC REL TP53
16
Show member pathways
12.04 CDK4 MDM2 MYC TP53
17 12.01 BCL6 MDM2 PRDM1 TP53
18 11.92 BCL6 MDM2 MYC TP53
19 11.91 BCL6 IRF4 MYC TP53
20 11.88 CDK4 MDM2 MYC TP53
21
Show member pathways
11.81 IRF4 MYD88 REL
22 11.79 BCL10 CARD11 MALT1 MYD88
23 11.76 CDK4 MYC TP53
24 11.74 CDK4 MYC TP53
25 11.72 BCL10 BCL6 CARD11 IRF4 MALT1 MYD88
26 11.7 CDK4 MDM2 MYC TP53
27
Show member pathways
11.68 MDM2 PRDM1 TP53
28 11.6 CDK4 MDM2 MYC TP53
29
Show member pathways
11.52 MDM2 REL TP53
30 11.38 BCL6 CD5 MME PRDM1 TNFRSF8
31 11.37 CDK4 MDM2 MYC TP53
32 11.25 CDK4 MDM2 TP53
33 11.01 MDM2 MYC TP53
34
Show member pathways
11 MDM2 MYC TP53
35 11 CDK4 MDM2 MYC REL TP53

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 BCL10 BCL6 CDK4 EZH2 FOXP1 IRF4
2 protein complex GO:0043234 9.17 BCL10 CDK4 MALT1 MDM2 MYC MYD88
3 CBM complex GO:0032449 9.16 BCL10 MALT1
4 cytoplasm GO:0005737 10.1 BCL10 CARD11 CDK4 EZH2 GCSAM MALT1
5 nucleoplasm GO:0005654 10.02 BCL6 CDK4 EZH2 FOXP1 IRF4 MDM2

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.95 BCL6 EZH2 FOXP1 MDM2 PASD1 TP53
2 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.95 BCL6 EZH2 MDM2 MYC PRDM1 REL
3 negative regulation of apoptotic process GO:0043066 9.93 BCL6 MALT1 MDM2 MYC MYD88 TP53
4 positive regulation of apoptotic process GO:0043065 9.92 BCL10 BCL6 CDK4 TNFRSF8 TP53
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 BCL10 CARD11 MALT1 MYD88
6 cellular response to mechanical stimulus GO:0071260 9.78 BCL10 MYD88 TNFRSF8
7 regulation of inflammatory response GO:0050727 9.77 BCL6 FOXP1 MYD88
8 regulation of apoptotic process GO:0042981 9.77 BCL10 BCL6 CARD11 MALT1 TP53
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 FOXP1 MYC MYD88
10 positive regulation of cell cycle GO:0045787 9.69 CDK4 MDM2 MYC
11 regulation of cell proliferation GO:0042127 9.65 BCL6 CDK4 EZH2 MYD88 PRDM1
12 cellular response to estrogen stimulus GO:0071391 9.64 MDM2 MYC
13 response to molecule of bacterial origin GO:0002237 9.64 BCL10 MALT1
14 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.63 CARD11 IRF4
15 replicative senescence GO:0090399 9.62 MME TP53
16 immunoglobulin mediated immune response GO:0016064 9.62 BCL10 MYD88
17 positive regulation of histone deacetylation GO:0031065 9.61 BCL6 TP53
18 negative regulation of B cell apoptotic process GO:0002903 9.59 BCL6 FOXP1
19 regulation of tumor necrosis factor production GO:0032680 9.58 FOXP1 MYD88
20 response to fungus GO:0009620 9.57 BCL10 MALT1
21 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.56 CDK4 MYC
22 regulation of T cell receptor signaling pathway GO:0050856 9.55 BCL10 MALT1
23 regulation of gene expression GO:0010468 9.55 CDK4 EZH2 MDM2 MYC MYD88
24 heart valve development GO:0003170 9.54 MDM2 PRDM1
25 positive regulation of T cell activation GO:0050870 9.5 BCL10 CARD11 MALT1
26 cellular response to actinomycin D GO:0072717 9.43 MDM2 TP53
27 negative regulation of gene expression GO:0010629 9.35 EZH2 MDM2 MYC PRDM1 REL
28 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.02 BCL10 CARD11 MALT1 MYD88 REL
29 innate immune response GO:0045087 10.03 BCL10 MALT1 MYD88 PRDM1 REL

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.8 BCL6 FOXP1 IRF4 MYC PRDM1 REL
2 protease binding GO:0002020 9.54 BCL10 MALT1 TP53
3 sequence-specific DNA binding GO:0043565 9.5 BCL6 EZH2 FOXP1 IRF4 MYC PRDM1
4 regulatory region DNA binding GO:0000975 9.4 EZH2 IRF4
5 kinase activator activity GO:0019209 9.32 BCL10 MALT1
6 protein self-association GO:0043621 9.02 BCL10 FOXP1 MALT1 MYD88 TP53
7 protein binding GO:0005515 10.11 BCL10 BCL6 CARD11 CD5 CDK4 EZH2

Sources for Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....